A randomized, multicenter phase III trial of bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer


Yalcin S., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., ...More

JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.4, 2011 (SCI-Expanded) identifier